Sutent
Immunicum's ilixadencel receives Renegerative Medicine Advanced Therapy from the FDA
The development of Immunicum's lead candidate, ilixadencel, just took a major step forward when the project received a so-called Renegerative Medicine Advanced...
Immunicum presented positive phase II data from MERECA
Every year, doctors, researchers and biotechnology companies gather in...
Complete tumor response measured in Immunicum's kidney cancer study
This morning, the cancer company Immunicum was able to announce very positive results...
Keytruda takes leadership position in kidney cancer
In 2019, there will be around 73,820 new cases of...